Business
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET --\n NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it will host an investor conference call to discuss detailed results from the pivotal, Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The conference call will follow the presentation of this data at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. The investor conference call is scheduled for Friday, May 29, 2020 at 1:00 p.m. ET. As previously reported, the BOSTON study met its primary endpoint with a significant increase in progression-free survival in patients with multiple myeloma following one to three prior lines of therapy. Details for the ASCO 2020 Virtual Scientific Program presentation are as follows: Late-breaking Oral Presentation Title: Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Patients with Multiple Myeloma (MM) After 1-3 Prior Therapies: Initial Results of the Phase 3 BOSTONPresenter: Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of MedicineAbstract #: 8501Session: Hematologic Malignancies—Plasma Cell DyscrasiaDate and time: Friday, May 29, 2020, 8:00 a.m. – 11:00 a.m.URL: https://meetinglibrary.asco.org/record/186143/abstract Conference Call Information Karyopharm will host a conference call Friday, May 29, 2020, at 1:00 p.m. Eastern Time, to discuss the detailed Phase 3 BOSTON study results. To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference ID 2049236. A live audio webcast of the call will be available under \"Events & Presentations\" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event. About XPOVIO® (selinexor) XPOVIO...